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Current Opinion
Introduction
It is no mystery that, when we as surgeons make clinical
decisions, we rely on previous experience as well as available
scientific evidence. Our experience develops from the under-
standing of the pathophysiology of a disease and the introduc-
tion of procedures to alter the process. Scientific evidence
becomes available when close observations of the results of the
procedure are reported.1 In the surgical literature, these re-
ports have typically consisted of case reports (arbitrarily de-
fined as 10 or fewer subjects) and case series.
Design of the study
A study design is complex and involves a number of decisions.
The most fundamental is whether to stand apart from the
events taking place in the study subjects (in an observational
study), or to test the effects of an intervention on these events
(in an experiment).2 Case series and case control series are
examples of observational studies. Cohort studies and
randomized controlled trials are interventional studies. The
randomized controlled trial is the only study design that must
be prospective, while all others can be designed as retrospective
or prospective studies (Table 1). With observational designs,
the measurements can be done on a single occasion (cross-
sectional study) or over a period of time (longitudinal study).
Levels of evidence
There are several grading systems for assessing the level of
evidence provided by a study.3,4 The first was developed by the
Canadian Task Force on the Periodic Health Examination in
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the 1970s (Table 2) and was adopted by the US Task Force.
While differing in some respects, most systems consider the a
priori design of the study and the actual quality of the study. In
the hierarchy of study design classification, the case series is
the weakest in determining the effectiveness of treatment
(level 3), while a randomized controlled trial will provide the
best evidence (level 1) when properly executed.
Randomized clinical trial
Controlled clinical trials are randomized, prospective studies
designed to evaluate the effectiveness of new treatments and
procedures. Patients are randomly assigned to intervention
and control groups. Usually, the control group receives the
standard treatment, or, in some trials, a placebo. Some studies
are designed to evaluate more than one experiment or alterna-
tive treatment, and patients are randomized to more than one
treatment arm. After treatment is administered, the groups are
compared on outcomes of intent, such as mortality, morbidity
and change in patient function status. A very important aspect
of randomized clinical trials is adherence to the Declaration of
Helsinki of 1964 and compliance with regulatory human
research requirements (Good Clinical Practice guidelines).
Timing of a randomized clinical trial
Once drugs and procedures of unproved clinical benefit have
become part of general medical practice, performing an ad-
equate clinical trial becomes difficult ethically and logistically.
Some people advocate instituting clinical trials as early as
possible in the evaluation of new therapies. The trials, however,
must be feasible. Assessing feasibility takes into account sev-
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eral factors. Before conducting a trial, an investigator needs to
have the necessary knowledge and tools, and know something
about the safety of the intervention, outcomes to assess, and
the techniques to do so. Conducting clinical trials of adequate
magnitude is costly and should be done only when prelimi-
nary evidence of the efficacy of an intervention looks promis-
ing enough to warrant the effort and expense involved or there
is disagreement in the clinical community about comparative
safety and efficacy.
When a new surgical technique is in development, it is
probably too early to conduct a large randomized trial. The
technique may be in a period of rapid refinement. There is also
likely to be a relatively small number of surgeons who can
perform the procedure. There may not be preliminary safety or
efficacy data to justify subjecting a large number of people to
the procedure. On the other hand, once a procedure has gained
widespread acceptance, it may be too late to conduct a
randomized study. Between these two extremes, a promising
treatment emerges, surgeons and patients become familiar
with the technique, and safety and efficacy data accumulate,
usually from case reports, case series and small studies. At
some point in this process, the general perception of the
usefulness of the emerging treatment is in a state of equipoise,
that is, opposing viewpoints are held in balance and there is
general consensus that the efficacy and safety of the new
treatment in comparison with existing treatments remains an
open question. At this time, justification for a randomized
clinical trial is strongest.5 In practice, though, it may be diffi-
cult at this time to find surgeons whose opinion is truly in
equipoise. While equipoise may exist among the community
of surgeons, that is, half believing the treatment is effective,
half believing it is not, individual surgeons may have a definite
preference and may be unwilling to randomize patients to
what they consider an inferior treatment. Even so, the window
of time during which equipoise exists is the optimal time to
conduct the randomized trial.6
Ethics of randomized trials
People have debated the ethics of clinical trials for as long as
they have been done. The arguments have changed over the
years and, perhaps, have become more sophisticated.7 Ethical
issues centre in general around a physician’s obligations to
his/her patient versus societal good, informed consent,
randomization, the use of placebo-control groups, and the
inclusion of women, children, the elderly and minorities.8,9
Studies that require intervention in vulnerable populations,
especially those with diminished ability to make decisions
about participation, raise important ethical issues about the
protection or overprotection of such populations.10 Studies
that continue to enrol participants after trends in the data
have appeared have raised some of the controversy which,
increasingly, is being managed by setting up data and safety
monitoring committees.11,12 A well-designed trial can answer
important public health questions without impairing the
welfare of individuals. There may, at times, be conflicts be-
tween a physician’s perception of what is good for his/her
patient and the needs of the trial. In such instances, the needs
of the participants should predominate. Study design, espe-
cially sample-size determination, needs to take this clinical
ethical concern into account.
Proper informed consent is essential and has been so at
Table 1. Hierarchy of study designs
Control group Prospective follow-up Random allocation of subjects
Case series No No No
Case control study Yes No No
Cohort study Yes Yes No
Randomized controlled trial Yes Yes Yes
Table 2. Level of evidence
I Evidence obtained from ≥ 1 properly randomized controlled trial
II-1 Evidence obtained from well-designed controlled trials without randomization
II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from > 1 centre or research group
II-3 Evidence obtained from comparison between times or places with or without the intervention. Dramatic results in
   uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could be included in this category
III Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees
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least since the Nuremberg Code from 1947. The requirements
of the US Department of Health and Human Services13 and
the International Ethical Guidelines for Biomedical Research
Involving Human Subjects provide detailed and practical guid-
ance about the information that needs to be conveyed to
potential subjects. Several investigators have shown that sim-
ply adhering to legal requirements does not ensure informed
consent,14,15 underscoring the need for sustained attention
not just to the informed consent form but also to the overall
informed consent process. In many clinical trial settings,
though, true informed consent can be obtained. The situa-
tions where participant enrolment must be done immediately,
in comatose patients, or in highly stressful circumstances and
where the prospective participants are minors or not fully
competent to understand the study, are more complicated and
may not have optimal solutions.5
Randomization has generally been more of a problem for
physicians and investigators than for participants,16 because
chance assignment of treatment would not be acceptable as
the standard of care in clinical practice. The obligation to
random assignment should only apply if the investigator does
not believe that a preferred therapy exists. If the physician does
believe reliably that there is a preferred treatment, then that
physician should not participate in the trial. On the other
hand, if the investigator truly cannot say that one treatment is
better than another, there should be no ethical problem with
randomization. Such judgements regarding efficacy obvious-
ly vary among investigators. As it may be unreasonable to ex-
pect that an individual investigator has no preference, not only
at the start of a trial but during its conduct, the concept of
“clinical equipoise” has been proposed.17 In this concept, the
presence of uncertainty as to the benefits or harm from an
intervention among the expert medical community, rather
than of the individual investigator, is justification for a clinical
trial. Similarly, the use of a placebo is acceptable if there is no
known best therapy and in other special circumstances (e.g.
the commonly used therapy is poorly tolerated).18 Of course,
all participants must be told that there is a specified probability,
for example, 50%, of receiving placebo. The use of a placebo
also does not imply that control group participants will receive
no treatment. In many trials, the objective is to see whether a
new intervention plus standard care is better or worse than a
placebo plus standard care. In all trials, there is the ethical
obligation to allow the best standard care to be used.7 It is also
important to emphasize that confidence in the integrity of the
trial and its results is essential to every trial. If, through intent
and/or inadvertent actions, that confidence is impaired, not
only have the participants and, potentially, others in the com-
munity been harmed, the trial loses it rationale and ability to
influence science and medical practice.7
Limitations of randomized clinical trials
Randomized clinical trials tend to take a long time to complete
because of the time required for planning, accruing and fol-
lowing patients, and analysing results. As a consequence, re-
sults may not be available for many years. Clinical trials are
also expensive to perform, although their costs may be recu-
perated if ineffective treatments are abandoned and effective
treatments are implemented.19 The results of a randomized
clinical trial may not be generalizable or applicable to all
patients with the disease because of the strict inclusion and
exclusion criteria and inherent differences in patients who
volunteer for trials. In addition, not all patients will respond
similarly to treatment. Another limitation is that in situations
where the disease or outcome is rare or only occurs after a long
period of follow-up, randomized clinical trials are difficult or
not feasible. Also, as discussed above, the ethics of performing
a randomized clinical trial are controversial and some clini-
cians may feel uncomfortable with randomizing their patients
when they believe one treatment to be superior, even if that is
based only on anecdotal evidence. In randomized trials, there
are also issues of special concern unique to surgical trials.20
The issue of standardization of the procedure is of major
importance in surgical trials. Standardization is difficult be-
cause surgeons may vary in their experience with and ability to
perform a surgical technique, there may be individual prefer-
ences in performing the procedure, and technical modifica-
tions may occur as the procedure evolves. Moreover, differ-
ences in perioperative and postoperative care may also have an
impact on the outcome. There are two issues related to stand-
ardization of the procedure. First, there is the issue of who
should perform the procedure – experts only or surgeons of
varying ability. Second, there is the issue of standardization of
the procedure so that it is performed similarly by all surgical
participants and it can be duplicated following publication
of the trial results. The implications of these two issues are
different and strategies to address them differ.21
The first issue is analogous to assessing compliance in a
medical trial. Thus, if the procedure is performed by experts
only in a very controlled fashion, this is analogous to an
efficacy trial. The advantage of such a trial is that if the pro-
cedure is truly superior to the other intervention, then this
design has the greatest likelihood of detecting a difference.
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The disadvantage obviously is that the results are less
generalizable. Like most issues in clinical trials, there is no
right or wrong answer.21 No matter how many surgeons are
involved in the trial and that investigators want to mimic
routine practice, there must be at least a certain amount of
standardization so that readers of the trial results can under-
stand what was done and can duplicate the procedure in their
own practice. There are several strategies to ensure a minimum
standard. First, all surgeons should agree on the performance
of the critical aspects of the procedure. It may not be necessary
to have agreement with all of the technical aspects, but there
should be consensus on those that are deemed important.
Furthermore, if there are aspects of the perioperative and
postoperative care that have an impact on outcome, they
should be standardized. Teaching sessions may be held pre-
operatively and feedback given to surgeons on their per-
formance during the trial. In addition, obtaining documenta-
tion that the procedure has been performed satisfactorily may
contribute to ensuring that the surgery is performed adequate-
ly. Finally, patients are usually stratified according to surgeon
or centre to ensure balance in case there are differences in sur-
gical technique between centres or surgeons.
Blinding is often a difficult issue in surgical trials. It may
not be an issue if two surgical procedures are being compared.
There is often a placebo effect of surgery. Performing sham
operations might be ethically difficult but not unfeasible. The
lack of blinding is especially worrisome if the primary out-
come is a change in symptoms or quality of life rather than
a hard outcome measure such as mortality or morbidity. In
these situations, if a hard outcome measure is also used and it
correlates with the patient assessment, there is less concern
about the possibility of bias. An independent assessor who is
unaware of the treatment group that the patient is in may
perform assessments. If criteria used to define an outcome are
explicitly specified a priori, it may minimize or eliminate bias.
Investigators may also choose, in this situation, to have a
blinded panel review the results of tests to ensure that they
meet the criteria.
Finally, patient issues may be of greater concern in surgical
trials. In a medical trial, patients may be randomized to either
treatment arm with the possibility that, at the conclusion of
the trial, they can receive the more efficacious treatment if the
disease is not progressive and the treatment is reversible.
Surgical procedures, however, are almost always permanent.
This may be of particular concern if a medical therapy is being
compared to a surgical procedure and the procedures differ in
their magnitude or invasiveness. Patients may have a prefer-
ence for one or the other treatment and, therefore, refuse to
participate in the trial. There also tends to be more emotion
involved with surgery, and patients may be less willing to leave
to chance the decision as to which procedure will be performed.
Surgeons themselves may feel uncomfortable in discussing
the uncertainty of randomization with patients requiring
surgery.22 Thus, accruing patients for surgical trials may be
more difficult than for medical trials.
Study protocol
Every well-designed clinical trial requires a protocol. The study
protocol can be viewed as a written agreement between the
investigator, the participant and the scientific community.7
The protocol provides the background, specifies the objectives,
and describes the design and organization of the trial. Every
detail explaining how the trial is carried out does not need to
be included, provided that there is a comprehensive manual of
procedures that contains such information. The protocol
serves as a document to assist communication among those
working in the trial.
The protocol should be developed before the beginning
of participant enrolment and should remain essentially un-
changed except perhaps for minor updates. Careful thought
and justification should go into any changes.
Statistical power and the planning of
clinical trials
Investigators use power analysis to determine the probabi-
lity that a given study will reject the null hypothesis when it is,
in fact, false. In other words, power analysis determines the
chance of detecting a true positive result. By tradition, re-
searchers consider a study to be adequately powered if it has at
least an 80% chance of detecting a clinically significant effect
when one exists. This exact value is arbitrary; higher power will
always be preferable and should be set with consideration of
the importance of limiting both false-negative (i.e. type 2
errors) and false-positive conclusions (i.e. type 1 errors).23
To calculate a study’s power to detect a given effect, inves-
tigators use a set of other variables, including the number of
individuals to be enrolled, the expected variability of their
outcomes, and the chosen probability of making a type 1 er-
ror. Reformulating these variables allows one to calculate the
number of study participants needed to detect a clinically
important effect size with acceptable power. Although con-
sensus among reasonable clinicians will generally enable
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determinations of how small an effect would be clinically
important to detect, disagreement about this value may oc-
casionally emerge. In such cases, a three-tiered, hierarchical
approach for investigators to use the effect size to be entered
into sample size calculations is advocated.23 First, when em-
pirical definitions of clinically meaningful effects exist, such as
in the percentage reduction of reported pain necessary to
define analgesic efficacy,24 those values ought to be used.
Second, if there is neither clinical consensus nor empirical
evidence to guide definitions of clinically important effects,
but data from earlier trials or observational studies reliably
indicate an intervention’s plausible effect, this value may be
used. Finally, if none of the foregoing criteria are met, then
previously published definitions of moderate effect sizes such
as those described by Cohen should be used.25 Trials that
cannot reliably detect effect sizes defined using this hierarchi-
cal approach may be defined as underpowered.23 Holpern et
al conclude that underpowered trials are ethical in only two
situations:23 small trials of interventions for rare diseases in
which investigators document explicit plans for including
their results with those of similar trials in a prospective meta-
analysis, and early-phase trials in the development of drugs
or devices, provided they are adequately powered for defined
purposes other than randomized treatment comparisons. In
both cases, investigators must inform prospective subjects
that their participation may only indirectly contribute to
future health care benefits.
Conclusions
There is certainly a perception held by others that surgeons are
not adequately assessing surgical procedures.21,26 In an edito-
rial in the Lancet in 1996, entitled, “Surgical research or comic
opera: questions, but few answers”, Richard Horton criticized
surgeons for their high reliance on case studies and stated that,
if surgeons wished to retain their academic reputation, they
must find imaginative ways to collaborate with epidemio-
logists to improve the design of the case series and to plan
randomized trials.27 Furthermore, he quoted a medical
statistician, Major Greenwell, who stated, “I should like to
shame surgeons out of comic opera performances which they
suppose are statistics of operations.”27 This quote dates back
to 1923. In a similar condemnation, Spodick complained of
“the repeated reporting of biased data from uncontrolled or
poorly controlled trials, giving an illusion of success due to
sheer quantity but that a thousand zeros look impressive on
paper, but they still amount to zero”.27
With increasing pressure from government, third-party
payers and even patients, there will be greater emphasis to make
therapeutic decisions on the basis of sounder evidence. Thus,
we must look at ways to overcome methodological and feasibil-
ity problems and perform high-quality randomized controlled
trials addressing important clinical issues. In those situations
where it is deemed unfeasible to perform a randomized
controlled trial, we need to look at alternatives that may be
less rigorous than the randomized controlled trial, such as
analytical case-controlled or cohort studies, but more rigorous
than uncontrolled descriptive case series or cross-sectional
studies.20 The goal should be to bring surgical innovation and
development up to the standards of evidence-based medicine,
to which surgical research makes an essential contribution.
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